Found: 4
Select item for more details and to access through your institution.
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
- Published in:
- Cytometry. Part A, 2019, v. 95, n. 3, p. 279, doi. 10.1002/cyto.a.23693
- By:
- Publication type:
- Article
Response to: Interference of daratumumab on the serum protein electrophoresis.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2017, v. 55, n. 2, p. e29, doi. 10.1515/cclm-2016-1026
- By:
- Publication type:
- Article
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2016, v. 54, n. 6, p. 1095, doi. 10.1515/cclm-2015-1031
- By:
- Publication type:
- Article
The Effect of Clinically Relevant Concentrations of Daratumumab on the Performance of Freelite® Immunoassays.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e127, doi. 10.1016/j.clml.2017.03.231
- By:
- Publication type:
- Article